Repurposed Therapeutic Agents Targeting the Ebola Virus

Added June 20, 2019

Citation: Sweiti H, Ekwunife O, Jaschinski T, Lhachimi SK. Repurposed therapeutic agents targeting the Ebola virus: a systematic review. Current Therapeutic Research. 2017 Jan 1;84:10-21.

Summary: Repurposed drugs for the treatment of Ebola Virus Disease (EVD) have not been recommended for use.

Eleven repurposed drugs were reviewed for the treatment of EVD. Prior to recommending these repurposed drugs, strong evidence about the quantity and quality of the drugs needs to be established from comprehensive pre-clinical and clinical trials.

EVD repurposed drugs are drugs that have already been approved and established for a different therapeutic use, but have also been identified with the potential to have anti-EVD therapeutic effects. As drug development for anti-EVD agents have been overlooked by pharmaceutical companies and investors, investigating repurposed drugs will reduce the cost and shorten the time needed to develop and transport the drug. Based on the thirty-seven studies reviewed, a total of eleven repurposed drugs (Chloroquine, Amodiaquine, Toremiphene and Clomiphene, IFNs, Convalescent blood products, Amiodarone, Sertraline, Bepridil, Favipiravir, and Azithromycin) were identified, with varying degrees of evidence supporting the mechanism and usage as an anti-EVD therapeutic agent. It is recommended that pre-clinical and clinical trials are conducted to find evidence that may prove the efficacy of the repurposed drugs mentioned.


Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on Ebola but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about Ebola on the basis of this summary alone.